Clinical Policy Title: Phototherapy and photochemotherapy for skin conditions

Clinical Policy Title: Phototherapy and photochemotherapy for skin conditions Clinical Policy Number: 16.02.04 Effective Date: October 1, 2015 Initial Review Date: May 20, 2015 Most Recent Review Date: May 1, 2018 Next Review Date: May 2019 Policy contains: Photochemotherapy. Phototherapy. Psoralen ultraviolet A (PUVA). Psoriasis. Related policies: None. ABOUT THIS POLICY: Select Health of South Carolina has developed clinical policies to assist with making coverage determinations. Select Health of South Carolina s clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peerreviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of medically necessary, and the specific facts of the particular situation are considered by Select Health of South Carolina when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. Select Health of South Carolina s clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. Select Health of South Carolina s clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, Select Health of South Carolina will update its clinical policies as necessary. Select Health of South Carolina s clinical policies are not guarantees of payment. Coverage policy Select Health of South Carolina considers the use of phototherapy and photochemotherapy (psoralen ultraviolet A [PUVA]) to be clinically proven and, therefore, medically necessary for the following skin conditions after conventional therapies have failed: Severe refractory atopic dermatitis/eczema. Mycosis fungoides/sézary syndrome (cutaneous T-cell lymphoma). Psoriasis. Vitiligo (Mehta, 2016; NICE, 2012; Olsen, 2016; Sidbury, 2014; Taieb, 2013). Select Health of South Carolina considers the use of phototherapy at home to be investigational and, therefore, not medically necessary. Limitations: All other uses of PUVA are not medically necessary, including, but not limited to, treatment for the following conditions: 1

Keratosis follicularis. Lichen amyloidosis. Lichen myxedematosus. Melasma. Low skin tolerance for sunlight. Alternative covered services: Biologic systemic agents, nonbiologic systemic agents, and phototherapy including broadband ultraviolet B (BB-UVB) and narrowband ultraviolet B (NB-UVB). Background Ultraviolet light a cause of sunburns, wrinkles, and skin cancer can be used in a medical setting as therapy for certain hard-to-treat skin problems and other medical conditions. The main forms of ultraviolet light are ultraviolet A (UVA) and ultraviolet B (UVB). PUVA is a topical treatment of disease by exposure to light at a specific portion of the solar spectrum, 320 to 400 nanometers in wavelength. Psoralens are chemicals found in plants that can absorb UV light. PUVA treatment for various skin conditions typically involves administration of an oral drug (e.g., methoxypsoralen) followed by exposure to UVA 45 to 60 minutes later. Other forms of PUVA include: Topical PUVA, with subsequent UVA exposure. Bath PUVA, which is not approved and rarely used in the United States. Paint PUVA, used locally on palms and plantar surfaces of the feet with 8-methoxypsoralen ointment or lotion applied directly to lesions. Soak PUVA, in which the area is immersed in a basin of water containing 8- methoxypsoralen. Originally, PUVA was developed for psoriasis, a relatively common skin disorder. It is also used for conditions such as vitiligo and mycosis fungoides (the most common type of T-cell lymphoma). While mild psoriasis can often be controlled by topical medications, severe cases often require treatments involving UVA light exposure. Before initiating PUVA therapy, other types of treatment should be discussed with the patient. The potential for PUVA to increase the risk of skin cancer, especially when treating psoriasis, should also be discussed. Persons at elevated risk for skin cancer from PUVA include children and persons with a genetic predisposition, a history of skin cancer, or a history of at least 150 prior PUVA treatments. Types of toxicity to PUVA includes erythema, pruritus, xerosis, irregular pigmentation, and gastrointestinal symptoms. Most toxicity can be avoided by altering or dividing the dose. Whether PUVA raises the risk of melanoma is controversial. When administered to pregnant women, PUVA has been 2

associated with a rise in low-weight births, but not congenital anomalies. An expert panel concluded that PUVA is contraindicated for patients with lupus erythematosus, porphyria, or xeroderma pigmentation (Menter, 2010). Caution should be exercised for patients with skin types I and II who tend to burn easily, with a history of arsenic intake, with a likelihood of requiring cyclosporin or methotrexate with previous ionizing radiation therapy, or with a history of melanoma or nonmelanoma skin cancer (Cole, 2017). PUVA-related guidelines are often specific to a patient s condition, e.g.: A 2014 practice guideline by the American Academy of Dermatology on dermatitis treatment recommended phototherapy as a second-line treatment if emollients, topical steroids, and calcineurin inhibitors have failed, and that phototherapy may be considered for home use if patients are unable to receive the treatment in an office setting (Sidbury, 2014). A 2012 guideline on psoriasis from the National Institute for Health and Clinical Excellence (NICE) suggests offering NB-UVB phototherapy to psoriasis patients whose condition cannot be controlled with topical treatments alone, but recommends not using any type of phototherapy as maintenance therapy (NICE, 2012). A 2016 review of guidelines for psoriasis concludes that NB-UVB is an effective treatment option for psoriasis (Mehta, 2016). A 2011 American Academy of Dermatology guideline on psoriasis observes that PUVA is more effective than NB-UVB for thick lesions, while NB-UVB generally results in shorter remission (Menter, 2011). A 2012 guideline on alopecia areata from the British Association of Dermatologists recommends against PUVA use due to potentially serious side effects and inadequate evidence of efficacy (Messenger, 2012). A 2016 guideline on mycosis fungoides and Sézary syndrome, for which ultraviolet light is often used, suggests a more refined guideline based on patient stage and centers, and in combination with other agents in practice and clinical trials (Olsen, 2016). A 2013 guideline recommends PUVA as a second-line therapy (behind NB-UVB) for vitiligo, along with PUVA in various combination therapies for the disease (Taieb, 2013). Searches Select Health of South Carolina searched PubMed and the databases of: UK National Health Services Centre for Reviews and Dissemination. Agency for Healthcare Research and Quality s National Guideline Clearinghouse and other evidence-based practice centers. The Centers for Medicare & Medicaid Services (CMS). We conducted searches on March 15, 2018. Search terms were: phototherapy," "photochemotherapy," PUVA therapy, UVA, UV-B, PUVA therapy home, psoriasis, vitiligo, eczema, mycosis, and fungoides. 3

We included: Systematic reviews, which pool results from multiple studies to achieve larger sample sizes and greater precision of effect estimation than in smaller primary studies. Systematic reviews use predetermined transparent methods to minimize bias, effectively treating the review as a scientific endeavor, and are thus rated highest in evidence-grading hierarchies. Guidelines based on systematic reviews. Economic analyses, such as cost-effectiveness, and benefit or utility studies (but not simple cost studies), reporting both costs and outcomes sometimes referred to as efficiency studies which also rank near the top of evidence hierarchies. Findings Psoriasis is the condition most studied for phototherapy outcomes. A systematic review of 29 articles (n = 675) of persons with palmoplantar pustular psoriasis found that phototherapy, ciclosporin, and topical corticosteroids each controlled the disease, with PUVA having greater efficacy than UVB therapy (Sevrain, 2014). Another meta-analysis of psoriasis (23 studies, n = 765) also found PUVA to be more efficacious than non-larger targeted UVB phototherapy, although both treatments had positive outcomes (Almutawa, 2015). PUVA s superiority to NB-UVB was also observed in a 2012 meta-analysis of 29 trials (n = 773) and accomplished these results in fewer sessions (Archier, 2012a). A 2013 Cochrane review of 13 trials (n = 662) on psoriasis found the PUVA vs. UVB comparison to be hampered by heterogenous evidence, and could not make a definitive conclusion on which was more effective (Chen, 2013). Phototherapy is generally found to work better as part of combination treatments, rather than as monotherapy, in psoriasis patients (Bailey, 2012). Another systematic review of 41 trials (n = 2416) found that PUVA was more effective than NB-UVB as a monotherapy, and NB-UVB worked better than BB-UVB and bath PUVA in treating adults with moderate to severe psoriasis (Almutawa, 2013). A systematic review of 21 randomized controlled trials (RCTs) including 961 patients determined that NB-UVB and UVA1 phototherapy in moderate to severe dermatitis were helpful, but data on PUVA use and phototherapy in children are scarce (Perez-Ferriols, 2015). Another systematic review of 19 studies (n = 905) found that UVA1 and NB-UVB were the most effective treatments for reducing signs and symptoms of dermatitis (Garritsen, 2014). Findings from 19 systematic reviews have determined that NB-UVB can be used effectively for chronic atopic eczema, and UVA used for acute eczema (Williams, 2008). A recent meta-analysis of 38 studies of persons with vitiligo compared NB-UVB phototherapy (n = 1,201) to PUVA phototherapy (n = 227). At six and 12 months of treatment, the UVB group had more at least mild responses (74.2 and 75.0 percent) than did the PUVA group (51.4 and 61.6 percent). Marked 4

responses were more common in the face and neck (44.2 percent) than in the trunk (26.1) and the extremities (17.3) after six months of UVB phototherapy (Bae, 2017). A literature review found that combination therapies for vitiligo, compared to monotherapy, were more effective, especially when phototherapy was included (Bacigalupi, 2012). A systematic review determined NB-UVB had fewer side effects and was marginally better than PUVA for vitiligo, and that (along with topical corticosteroids) it offers the greatest benefits of any vitiligo treatment (Whitton, 2015). A systematic review of seven studies (n = 232) comparing vitiligo treatment by PUVA and NB-UVB revealed no difference between the two on the rate of patients who achieved over 50 or over 75 percent re-pigmentation, both at p >.05 (Xiao, 2015). Mycosis fungoides is the most common cutaneous T-cell lymphoma, and conventional therapy is not always effective in treating it. A review of 20 papers documents photodynamic therapy as a promising and well-tolerated option for treating localized lesions, with excellent cosmetic outcomes (Xue, 2017). PUVA and NB-UVB monotherapy were found to be effective first-line interventions for mycosis fungoides; the effectiveness of PUVA either as maintenance therapy or combined with drugs as first-line therapy is uncertain, but may be beneficial for relapse and late-stage disease (Dogra, 2015). A Cochrane review of 14 studies (n = 675) was unable to determine relative efficacy between types of mycosis fungoides treatments (Weberschock, 2012). Risk of cancer from PUVA was the focus of a systematic review of 41 studies of chronic plaque psoriasis. Risk was elevated for non-melanoma skin cancer for squamous cell carcinomas, even at low exposures, with risk persisting after treatment cessation; for basal cell carcinoma in patients receiving more than 100 PUVA treatments; and for melanoma in persons receiving more than 200 PUVA treatments. No skin cancer risk was associated with NB-UVB use (Archier, 2012b). PUVA is usually administered in an outpatient setting, but this treatment is also available for home use. Research has yet to demonstrate the efficacy of home phototherapy, which has been used for years despite lack of a consensus on efficacy (Koek, 2006). Rajpara (2010) found home NB-UVB was as safe, effective, and cost-effective as outpatient treatment, was more convenient, and generated higher satisfaction (Rajpara, 2010). One study of home-based phototherapy found NB-UVB to be safer than PUVA (Lapolla, 2011). Regular skin examinations by a dermatologist should be performed as PUVA home treatments are conducted. But a Cochrane review failed to support or refute home-based phototherapy for non-hemolytic jaundice in infants over 37 weeks gestation (Malwade, 2014). Most recently, a systematic review of 23 articles observed high levels of patient satisfaction, high levels of safety, and mostly positive reports of high quality of life after home phototherapy (Franken, 2016). The issue of whether home phototherapy use is safe and effective remains unresolved. PUVA is used, sometimes effectively, for a variety of skin conditions for which the professional medical literature is limited. For example, in a Cochrane review of 16 studies (11 RCTs), PUVA treatment for cutaneous lichen planus had comparable outcomes to a PUVA bath and NB-UVB (Atzmony, 2016). A review of 14 studies (n = 64) of pediatric patients with pityriasis lichenoides determined that BB-UVB, 5

NB-UVB, and PUVA had initial clearance rates of 90 percent, 73 percent, and 83 percent, respectively, with recurrence rates of 23.1 percent, 0 percent, and 60 percent, respectively (Maranda, 2016). Policy updates: A total of two guidelines/other and five peer-reviewed references were added to, and six peer-reviewed references removed from, this policy in March 2018. Summary of clinical evidence: Citation Bae (2017) Comparison of phototherapy modes for vitiligo Almutawa (2015) PUVA, UVB and photodynamic therapy (PDT) for psoriasis Dogra (2015) Content, Methods, Recommendations Key points: Meta-analysis of 35 studies (n = 1428) comparing NB-UVB (n = 1,201) and UVA (n = 227) phototherapy for vitiligo. At six and 12 months after therapy, UVB resulted in a higher percent of patients with at least a mild response (74.2 and 75.0), compared to UVA (51.4 and 61.6). Percent of patients with marked responses was 44.2% in the face and neck, 26.1% on the trunk, and 17.3% on the extremities. Key points: Systematic review and meta-analysis of six RCTs and 17 case series. The primary outcome was 75% reduction in severity score from baseline. Overall quality: low with high risk of bias. Small sample size, study heterogeneity. PUVA had a statistically nonsignificant (P = 0.183) advantage over targeted UVB. The pooled effect estimate of topical PUVA, targeted UVB and PDT were 77%, 61% and 22%, respectively (15-case series). Topical PUVA and targeted UVB phototherapy are effective in treating localized psoriasis. PDT has low efficacy and high percentage of side effects. Key points: Phototherapy for mycosis fungoides (MF) Synthesis of 107 systematic reviews, meta-analyses, national guidelines, RCTs, prospective open label studies, and retrospective case series. For early-stage mycosis fungoides (stages IA, IB, and IIA): o PUVA is a safe, effective, and well tolerated first-line therapy (level of evidence [LOE] 1+, grade of recommendation B). o NB-UVB is comparable to PUVA but has less robust evidence (LOE 2++, grade B). o PUVA with methotrexate, bexarotene, or interferon-alpha-2b has unclear advantage over monotherapy. o NB-UVB preferred in patients with patches and thin plaques. o PUVA preferred for thick plaques and relapse after initial NB-UVB therapy. To induce remission, complete three treatment sessions per week of either PUVA phototherapy or NB-UVB phototherapy until complete remission. In cases of relapse, administer PUVA monotherapy or PUVA combined with adjuvants like methotrexate and interferon (LOE 2+, Grade B). For late-stage mycosis fungoides, above combination therapy may be first-line treatment (LOE 6

Citation Whitton (2015) Interventions for vitiligo Archier (2012) Content, Methods, Recommendations 3, grade C). No consensus regarding maintenance therapy with phototherapy once in remission. Routine maintenance PUVA therapy not recommended; reserved for early relapse after initial course of phototherapy (LOE 2+, Grade B). Bath-water PUVA has similar efficacy to oral PUVA and may be an alternative in case oral PUVA therapy cannot be administered (LOE 2-, Grade C). In pediatric mycosis fungoides and in hypopigmented mycosis fungoides, NB-UVB and PUVA may be tried (LOE 3, grade D). Key points: Cochrane review of 96 RCTs (4,512 total participants) of all interventions; three RCTs comparing NB-UVB with PUVA eligible for meta-analysis. Overall quality: low with high risk of bias. NB-UVB has fewer side effects and is marginally better than PUVA. Proportion of participants achieving > 75% repigmentation favored NB-UVB compared to PUVA. NB-UVB group reported less nausea in three studies (N = 156) and erythema in two studies (N = 106), but not itching in two studies (N = 106). Very few studies only assessed children or included segmental vitiligo. There is a need for follow-up studies to assess permanence of repigmentation and high-quality RCTs using standardized measures that address quality of life. Key points: Cancer risk of PUVA for psoriasis Systematic review of 41 studies of chronic plaque psoriasis treated with PUVA and NB-UVB. Risk elevated for squamous cell carcinomas after PUVA, even at low exposures; risk persists after treatment cessation. Risk elevated for basal cell carcinoma in patients receiving more than 100 PUVA treatments. Risk elevated for melanoma in persons receiving more than 200 PUVA treatments. No skin cancer risk associated with NB-UVB use. References Professional society guidelines/other: Ling TC, Clayton TH, Crawley J, et al. British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen-ultraviolet A therapy 2015. Br J Dermatol. 2016;174(1):24 55.. Cole GW. PUCA Therapy (Photochemotherapy). MedicineNet, last reviewed September 12, 2017. https://www.medicinenet.com/puva_therapy_photochemotherapy/article.htm#what_is_puva. Accessed March 14, 2018. Mehta D, Lim HW. Ultraviolet B phototherapy for psoriasis: review of practical guidelines. Am J Clin Dermatol. 2016;17(2):125 33. 7

Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Audiol. January 2010; 62(1): 114 35. Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M. British Association of Dermatologists guidelines for the management of alopecia areata 2012. Br J Dermatol. 2012;166(5):916 26. Morton C, Szeimies RM, Sidoroff A, et al. European Dermatology Forum Guidelines on topical photodynamic therapy. Eur J Dermatol. 2015;25(4):296 311. National Institute for Health and Clinical Excellence (NICE). Psoriasis: the assessment and management of psoriasis. October 2012; 61 p. (NICE clinical guideline; no. 153). https://www.nice.org.uk/guidance/cg153/chapter/1-guidance#phototherapy-broad--or-narrow-banduvb-light-and-puva. Accessed March 14, 2018. Olsen EA, Hodak E, Anderson T, et al. Guidelines for phototherapy of mycosis fungoides and Sezary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol. 2016;74(1):27 58. Sidbury R, Davis DM, Cohen DE, et al. guidelines of care for the management of atopic dermatitis. Section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327 49. Taieb A, Alomar A, Bohm M, et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013;168(1):5 19. Peer-reviewed references: Almutawa F, Thalib L, Hekman D, et al. Efficacy of localized phototherapy and photodynamic therapy for psoriasis: a systematic review and meta-analysis. Photodermatol Photoimmunol Photomed. 2015; 31(1): 5 14. Almutawa F, Alnomair N, Wang Y, Hamzavi I, Lim HW. Systematic review of UV-based therapy for psoriasis. Am J Clin Dermatol. 2013;14(2):87 109. Archier E, Devaux S, Castela E, et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012b;26 Suppl 3:22 31. Archier E, Devaux S, Castela E, et al. Efficacy of psoralen UV-A therapy vs. narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012a;26 Suppl 3: 11 21. 8

Atzmony L, Reiter O, Hodak E, Gdalevich M, Mimouni D. Treatments for cutaneous lichen planus: A systematic review and meta-analysis. Am J Clin Dermatol. 2016;17(1):11 22.. Bacigalupi RM, Postolova A, Davis RS. Evidence-based, non-surgical treatments for vitiligo: a review. Am J Clin Dermatol. 2012;13(4):217 37. Bae JM, Jung HM, Hong BY, et al. Phototherapy for vitiligo: a systematic review and meta-analysis. JAMA Dermatol. 2017;153(7):666 74. Bailey EE, Ference EH, Alikhan A, Hession MT, Armstrong AW. Combination treatments for psoriasis: a systematic review and meta-analysis. Arch Dermatol. 2012; 148(4): 511 22. Chen X, Yang M, Cheng Y, Liu GJ, Zhang M. Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis. Cochrane Database Syst Rev. 2013; 10: CD009481. Doi: 10.1002/14651858.CD009481.pub2. Dogra S, Mahajan R. Phototherapy for mycosis fungoides. Indian J Dermatol Venereol Leprol. 2015; 81(2): 124 135. Franken SM, Vierstra CL, Rustmeyer T. Improving access to home phototherapy for patients with psoriasis: current challenges and future prospects. Psoriasis (Auckl). 2016;6:55 64. Garritsen FM, Brouwer MW, Limpens J, Spuls PI. Photo(chemo) therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. Br J Dermatol. 2014;170(3):501 13. Koek MB, Buskens E, Bruijnzeel-Koomen CA, Sigurdsson V. Home ultraviolet B phototherapy for psoriasis: discrepancy between literature, guidelines, general opinions and actual use. Results of a literature review, a web search, and a questionnaire among dermatologists. Br J Dermatol. 2006;154(4):701 11. Lapolla W, Yentzer BA, Bagel J, Halvorson CR, Feldman SR. A review of phototherapy protocols for psoriasis treatment. J Am Acad Dermatol. 2011; 64(5): 936 49. Malwade US, Jardine LA. Home- versus hospital-based phototherapy for the treatment of nonhaemolytic jaundice I infants at more than 37 weeks gestation. Cochrane Database Syst Rev. 2014;(6):CD010212. Doi: 10.1002/14651858.CD010212.pub2. Maranda EL, Smith M, Nguyen AH, Patel VN, Schachner LA, Joaquin JJ. Phototherapy for pityriasis lichenoides in the pediatric population: A review of the published literature. Am J Clin Dermatol. 2016;17(6):583 91. 9

Perez-Ferriols A, Aranegui B, Pujol-Montcusi JA, et al. Phototherapy in atopic dermatitis: a systematic review of the literature. Actas Dermosifiliogr. 2015;106(5):387 401. Rajpara AN, O'Neill JL, Nolan BV, Yentzer BA, Feldman SR. Review of home phototherapy. Dermatol Online J. 2010; 16(12): 2. Sevrain M, Richard MA, Bametche T, et al. Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion. J Eur Acad Dermatol Venereol. 2014;28 Suppl 5:13 16. Weberschock T, Strametz R, Lorenz M, et al. Interventions for mycosis fungoides. Cochrane Database Syst Rev. 2012; 9: CD008946. Doi: 10.1002/14651858.CD008946.pub2. Whitton ME, Pinart M, Batchelor J, et al. Interventions for vitiligo. Cochrane Database Syst Rev. 2015; 2: CD003263. Doi: 10.1002/14651858.CD003263.pub5. Williams HC, Grindlay DJ. What s new in atopic eczema? An analysis of the clinical significance of systematic reviews on atopic eczema published in 2006 and 2007. Clin Exp Dermatol. 2008;33(6):685 88. Xiao BH, Wu Y, Sun Y, Chen HD, Gao XH. Treatment of vitiligo with NB-UVB: A systematic review. J Dermatolog Treat. 2015;26(4):340-6. Doi: 10.3109/09546634.2014.952610. Xue J, Liu C, Liu Y. Photodynamic therapy as an alternative treatment for relapsed or refractory mycosis fungoides: a systemic review. Photodiagnosis Photodyn Ther. 2017;17:87 91. CMS National Coverage Determinations (NCDs): 250.1 Treatment of Psoriasis. CMS website. http://www.cms.gov/medicare-coveragedatabase/details/ncd-details.aspx?ncdid=88&ver=1. Accessed March 14, 2018. Local Coverage Determinations (LCDs): L33918 Laser Treatment for Psoriasis. Effective date: October 1, 2015. https://www.cms.gov/medicarecoverage-database/details/lcddetails.aspx?lcdid=33918&ver=3&date=10%2f01%2f2015&docid=l33918&bc=iaaaabaaaaaa&. Accessed March 14, 2018. Commonly submitted codes Below are the most commonly submitted codes for the service(s)/item(s) subject to this policy. This is 10

not an exhaustive list of codes. Providers are expected to consult the appropriate coding manuals and bill accordingly. CPT Code Description Comment 96567 Photodynamic therapy by external application of light to destroy premalignant and/or malignant lesions of the skin and adjacent mucosa (eg, lip) by activation of photosensitive drug(s), each phototherapy exposure session 96912 Photochemotherapy; psoralens and ultraviolet A (PUVA) 96913 Photochemotherapy (Goeckerman and/or PUVA) for severe photoresponsive dermatoses requiring at least 4-8 hours of care under direct supervision of the physician (includes application of medication and dressings) ICD-10 Code Description Comment L20.82 Flexural eczema L20.84 Intrinsic (allergic) eczema L40.0 Psoriasis vulgaris L40.1 Generalized pustular psoriasis L40.2 Acrodermatitis continua L40.3 Pustulosis palmaris et plantaris L40.4 Guttate psoriasis L40.8 Other psoriasis L40.9 Psoriasis, unspecified L41.3 Small plaque parapsoriasis L41.4 Large plaque parapsoriasis L41.5 Retiform parapsoriasis L41.8 Other parapsoriasis L41.9 Parapsoriasis, L80 Vitiligo HCPCS Level II Code N/A Description Comment 11